Multicentric Castleman's disease (MCD) describes a heterogeneous group of disorders
involving proliferation of morphologically benign lymphocytes due to excessive …

Castleman disease (CD) describes a group of heterogeneous hematologic disorders with
characteristic histopathological features. CD can present with unicentric or multicentric …

Summary Background Multicentric Castleman's disease describes a group of poorly
understood lymphoproliferative disorders driven by proinflammatory hypercytokinaemia …

To better define the molecular basis of multiple myeloma (MM), we performed unsupervised
hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 …

To molecularly define high-risk disease, we performed microarray analysis on tumor cells
from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate …

Background High-dose therapy with melphalan can prolong survival among patients with
multiple myeloma. We assessed whether the addition of thalidomide, which has activity …

Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma
(MM), 5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 …

Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1
(CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously …

Using fluorescence in situ hybridization we investigated amplification of chromosome band
1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of …

F18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a powerful tool to
investigate the role of tumor metabolic activity and its suppression by therapy for cancer …